Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Large ribosomal subunit protein bL35m (MRPL35) is a nuclear-encoded protein that is incorporated into the large 39S subunit of the mitochondrial ribosome (mitoribosome)[3][5][7]. It is essential for mitochondrial protein synthesis and thus for proper mitochondrial function and cellular energy metabolism[5][2]. MRPL35 is robustly expressed in tissues and is highly conserved across species[3][2]. Dysfunction or altered expression of MRPL35 has been associated with changes in cell proliferation, invasion, and glutamine metabolism, particularly in the context of non-small cell lung cancer, where it promotes tumor growth by upregulating SLC7A5 expression[1]. Its core role is structural—helping assemble the mitoribosome for translation of mitochondrial mRNAs. While MRPL35 is not a classic druggable target (e.g., receptor or enzyme), recent research points to its potential as a therapeutic target due to its emergent roles in cancer metabolism[1]. There are currently no approved drugs targeting MRPL35, likely reflecting the essential nature of the mitochondrial translation machinery and the safety risks of systemic inhibition[2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Large ribosomal subunit protein bL35m (mitochondrial) (MRPL35).